Important data releases are on the cards for Rhythm, Wave and Supernus, among others.
But the Soloist trial suggests a benefit in heart failure with preserved ejection fraction, which might be good news for Lexicon’s SGLT2 rivals.
Omada is better funded than its digital health rival Livongo, but can it achieve a similar valuation?
At the US liver conference Inventiva will make a case for PPAR agonism, while Novo Nordisk and Gilead’s combo will be scrutinised in Nash.
Novo’s late-stage pipeline is set to balloon with three new pivotal trials planned; data due in Alzheimer’s could add a whole new storyline.